Abstract
Interactions between host and pathogenic microorganisms are common in nature and have a significant impact on host health, often leading to several types of infections. These interactions have evolved as a result of the ongoing battle between the host’s defense mechanisms and the pathogens’ invasion strategies. In this chapter, we will explore the evolution of host-pathogen interactions, explore their molecular mechanisms, examine the different stages of interaction, and discuss the development of pharmacological treatments. Understanding these interactions is crucial for improving public health, as it enables us to develop effective strategies to prevent and control infectious diseases. By gaining insights into the intricate dynamics between pathogens and their hosts, we can work towards reducing the burden of such diseases on society.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Woolhouse MEJ, Webster JP, Domingo E et al (2002) Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet 32:569–577
Cohen SB, Gern BH, Delahaye JL et al (2018) Alveolar macrophages provide an early mycobacterium tuberculosis niche and initiate dissemination. Cell Host Microbe 24:439–446
Singh R, Dwivedi SP, Gaharwar US et al (2020) Recent updates on drug resistance in mycobacterium tuberculosis. J Appl Microbiol 128:1547–1567
Anstee DJ (2010) The relationship between blood groups and disease. Blood 115:4635–4643
Franchini M, Bonfanti C (2015) Evolutionary aspects of ABO blood group in humans. Clin Chim Acta 444:66–71
Rowe JA, Handel IG, Thera MA et al (2007) Blood group O protects against severe plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A 104:17471–17476
Howes RE, Patil AP, Piel FB et al (2011) The global distribution of the Duffy blood group. Nat Commun 2:226
Stucki D, Brites D, Jeljeli L et al (2016) Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet 48:1535–1543
Duarte R, Lönnroth K, Carvalho C et al (2018) Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology 24:115–119
Freschi L, Vargas R, Husain A et al (2021) Population structure, biogeography and transmissibility of mycobacterium tuberculosis. Nat Commun 12:1–11
Sironi M, Cagliani R, Forni D, Clerici M (2015) Evolutionary insights into host-pathogen interactions from mammalian sequence data. Nat Rev Genet 16:224–236
Smith AC, Morran LT, Hickman MA (2022) Host defense mechanisms induce genome instability leading to rapid evolution in an opportunistic fungal pathogen. Infect Immun 90:e0032821
Papkou A, Schalkowski R, Barg MC et al (2021) Population size impacts host-pathogen coevolution. Proc Biol Sci 288:20212269
Lin MJ, Rachleff VM, Xie H et al (2022) Host-pathogen dynamics in longitudinal clinical specimens from patients with COVID-19. Sci Rep 12:1–11
Gu H, Quadeer AA, Krishnan P et al (2023) Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals. Nat Commun 14:1–14
Seid A, Berhane N, Abayneh T, Tesfaye S (2021) Impacts of pathogen-host-drug interaction in the evolution and spread of antimicrobial-resistant pathogens. Microbes Infect Dis 3:286–295
Rapisarda C, Tassinari M, Gubellini F, Fronzes R (2018) Using Cryo-EM to investigate bacterial secretion systems. Annu Rev Microbiol 72:231–254
Costa TRD, Felisberto-Rodrigues C, Meir A et al (2015) Secretion systems in gram-negative bacteria: structural and mechanistic insights. Nat Rev Microbiol 13:343–359
Miletic S, Goessweiner-Mohr N, Marlovits TC (2020) The structure of the type III secretion system needle complex. Curr Top Microbiol Immunol 427:67–90
Slater SL, Sågfors AM, Pollard DJ et al (2018) The type III secretion system of pathogenic Escherichia coli. In: Frankel G, Ron E (eds) Escherichia coli, a versatile pathogen, Current topics in microbiology and immunology, vol 416. Springer, Heidelberg, pp 51–72
Plano GV, Schesser K (2013) The Yersinia pestis type III secretion system: expression, assembly and role in the evasion of host defenses. Immunol Res 57:237–245
Maginnis MS (2018) Virus-receptor interactions: the key to cellular invasion. J Mol Biol 430:2590–2611
Grove J, Marsh M (2011) The cell biology of receptor-mediated virus entry. J Cell Biol 195:1071–1782
Handschuh J, Amore J, Müller AJ (2020) From the cradle to the grave of an infection: host-pathogen interaction visualized by intravital microscopy. Cytometry A 97:458–470
Chandra P, Grigsby SJ, Philips JA (2022) Immune evasion and provocation by mycobacterium tuberculosis. Nat Rev Microbiol 20:750–766
Thorne LG, Bouhaddou M, Reuschl AK et al (2022) Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature 602:487–495
Santacroce L, Charitos IA, Carretta DM et al (2021) The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. J Mol Med 99:93–106
Bour S, Perrin C, Akari H, Strebel K (2001) The human immunodeficiency virus type 1 Vpu protein inhibits NF-κB activation by interfering with βTrCP-mediated degradation of IκB. J Biol Chem 276:15920–15928
Zhang Y, Chen Y, Li Y et al (2021) The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci U S A 118:1–12
Piguet V, Trono D (2001) Living in oblivion: HIV immune evasion. Semin Immunol 13:51–57
Bernet J, Ahmad M, Mullick J et al (2011) Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity. Vaccine 29:7435–7443
Liszewski MK, Leung MK, Hauhart R et al (2006) Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and Variola and evidence for dimer formation. J Immunol 176:3725–3734
Saito F, Hirayasu K, Satoh T et al (2017) Immune evasion of plasmodium falciparum by RIFIN via inhibitory receptors. Nature 552:101–105
Zhou H, Xu M, Huang Q et al (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495–504
Brass AL, Dykxhoorn DM, Benita Y et al (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921–926
Appelberg R, Moreira D, Barreira-Silva P et al (2015) The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon-γ. Immunology 145:498–507
Singh V, Jamwal S, Jain R et al (2012) Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12:669–681
Boom HW, Schaible UE, Achkar JM (2021) The knowns and unknowns of latent mycobacterium tuberculosis infection. J Clin Invest 131:e136222
Glaziou P, Floyd K, Raviglione MC (2018) Global epidemiology of tuberculosis. Semin Respir Crit Care Med 39:271–285
Bagcchi S (2023) WHO’s global tuberculosis report 2022. Lancet Microbe 4:e20
Khan A, Singh VK, Hunter RL, Jagannath C (2019) Macrophage heterogeneity and plasticity in tuberculosis. J Leukoc Biol 106:275–282
Suárez I, Fünger SM, Rademacher J et al (2019) The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int 116:729–735
Dheda K, Gumbo T, Maartens G et al (2017) The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5:291–360
Sia JK, Rengarajan J (2019) Immunology of mycobacterium tuberculosis infections. Microbiol Spectr 7:1–37
Berns SA, Isakova JA, Pekhtereva PI (2022) Therapeutic potential of interferon-gamma in tuberculosis. ADMET DMPK 10:63–73
Alsultan A, Peloquin CA (2014) Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74:839–854
Zumla A, Chakaya J, Centis R et al (2015) Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 3:220–234
Menzeis D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146:340–354
Bouzeyen R, Javid B (2022) Therapeutic vaccines for tuberculosis: an overview. Front Immunol 13:1–10
UNAIDS. Fact Sheet (2022) World tuberculosis day. UNAIDS
Chou R, Evans C, Hoverman A et al (2019) Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force. J Am Med Assoc 321:2214–2230
Thompson MA, Aberg JA, Hoy JF et al (2012) Antiretroviral treatment of adult HIV infection. J Am Med Assoc 308:387–402
HHS panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (2022) 1–604. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
Meek TD (1992) Inhibitors of HIV-1 protease. J Enzyme Inhib Med Chem 6:65–98
Keedy KS, Pharm AD, Margolis DM (2010) Therapy for persistent HI. Trends Pharmacol Sci 31:206–211
Atta MG, De Seigneux S, Lucas GM (2019) Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol 14:435–444
Saag MS, Gandhi RT, Hoy JF et al (2020) Antiretroviral drugs for treatment and prevention of HIV infection in adults: recommendations of the international antiviral society-USA panel. J Am Med Assoc 324:1651–1669
Olliaro P, Wells TNC (2009) The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85:584–595
Expanded Table: Drugs for Malaria Prophylaxis (online only) (2023) The Medical Letter Inc. [Internet]. Available from: https://secure.medicalletter.org/TML-article-1575e
Wells TNC, Van Huijsduijnen RH, Van Voorhis WC (2015) Malaria medicines: a glass half full? Nat Rev Drug Discov 14:424–442
Palacpac NMQ, Horii T (2020) Malaria vaccines: facing unknowns. F1000Research 9:F1000
Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470–473
Drożdżal S, Rosik J, Lechowicz K et al (2021) An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 59:100794
Binns C, Low WY (2015) What is public health? Asia-Pac J Public Heal 27:5–6
Halaji M, Farahani A, Ranjbar R et al (2020) Emerging coronaviruses: first SARS, second MERS and third SARS-COV-2. Epidemiological updates of COVID-19. Infez Med 28:6–17
Cai J, Deng X, Yang J et al (2022) Modeling transmission of SARS-CoV-2 omicron in China. Nat Med 28:1468–1475
Houben RMGJ, Dodd PJ (2016) The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13:1–13
Rengganis Wardani DWS, Wahono EP (2017) Prediction model of tuberculosis transmission based on its risk factors and socioeconomic position in Indonesia. Indian J Commun Med 42:204208
Bastos SH, Taminato M, Fernandes H et al (2019) Sociodemographic and health profile of TB/HIV co-infection in Brazil: a systematic review. Rev Bras Enferm 72:1389–1396
Lange C, Chesov D, Heyckendorf J et al (2018) Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology 23:656–673
World Health organization. Global Tuberculosis report (2022) license: c. 2022. 68 p
Zou Z, Liu G, Hay SI et al (2022) Time trends in tuberculosis mortality across the BRICS: an age-period-cohort analysis for the GBD 2019. eClinicalMedicine 53:101646
Gelaw Y, Getaneh Z, Melku M (2021) Anemia as a risk factor for tuberculosis: a systematic review and meta-analysis. Environ Health Prev Med 26:1–15
Yen YF, Hu HY, Lee YL et al (2017) Obesity/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan. Int J Obes 41:971–975
Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2015
Hooper AT, Somersan-Karakaya S, McCarthy SE et al (2022) Casirivimab and imdevimab treatment reduces viral load and improves clinical outcomes in seropositive hospitalized COVID-19 patients with non-neutralizing or borderline neutralizing antibodies. MBio1 3:1–13
Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19 – final report. N Engl J Med 383:1813–1826
Cheng VCC, Lau SKP, Woo PCY, Kwok YY (2007) Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20:660–694
Liu P, Jiang JZ, Wan XF et al (2020) Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? PLoS Pathog 16:1–13
Tosta S, Moreno K, Schuab G et al (2023) Global SARS-CoV-2 genomic surveillance: what we have learned (so far). Infect genet Evol 108:105405
Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574
World Health Organization. HIV. THE GLOBAL HEALTH OBSERVATORY (2023). Available from: https://www.who.int/data/gho/data/themes/hiv-aids
Sohail M, Levitan EB, Rana AI et al (2020) Estimating the first 90 of the UNAIDS 90-90-90 goal: a review. J Int Assoc Provid AIDS Care 19:2325958220919290
HIV (2023). Available from: https://www.who.int/data/gho/data/themes/hiv-aids
World Health Organization (2016) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO, France
Murray CJL, Rosenfeld LC, Lim SS et al (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413–431
Barofsky J, Anekwe TD, Chase C (2020) Malaria eradication and economic outcomes in sub-Saharan Africa: evidence from Uganda. J Health Econ 44:118–136
Shretta R, Avanceña ALV, Hatefi A (2016) The economics of malaria control and elimination: a systematic review. Malar J 15:1–14
Snow RW, Guerra CA, Noor AM et al (2005) The global distribution of clinical episodes of plasmodium falciparum malaria. Nature 434:214–217
Alonso PL, Brown G, Arevalo-Herrera M et al (2011) A research agenda to underpin malaria eradication. PLoS Med 8:e1000406
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ponce-Cusi, R., Bravo, L., Paez, K.J., Pinto, J.A., Pilco-Ferreto, N. (2024). Host-Pathogen Interaction: Biology and Public Health. In: Medina, C., López-Baena, F.J. (eds) Host-Pathogen Interactions. Methods in Molecular Biology, vol 2751. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3617-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3617-6_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3616-9
Online ISBN: 978-1-0716-3617-6
eBook Packages: Springer Protocols